HomeBusinessHealthcare Industry Stock NewsLLY, NVO, PFE: The Impact Of A Weight Loss Pill

LLY, NVO, PFE: The Impact Of A Weight Loss Pill

The obesity market is still in its infancy, notes Jared Holz. He discusses health care stocks. He mentions that oral therapies are key as early data on oral therapies are encouraging, with Eli Lilly (LLY) and Novo Nordisk (NVO) leading. He talks about how LLY is developing Orforglipron as a weight-loss pill. He then goes over the impact of a "weight-loss" pill. He also highlights that NVO's drug Rybelsus is used for type-2 diabetes. Pfizer (PFE) is also developing Danuglipron for obesity treatment. Tune in to find out more about the stock market today.

Trading 360

29 Jun 2023

SHARE

ON AIR
11:00 pm
Trading 360
replay
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
education
3:30 pm
Your First Trade
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
education
7:00 pm
Your First Trade
REPLAY
7:30 pm
Trading 360
REPLAY
8:30 pm
Fast Market
REPLAY
9:30 pm
Next Gen Investing
REPLAY
education
10:30 pm
Your First Trade
REPLAY
ON AIR
11:00 pm
Trading 360
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now